William Blair analyst Brandon Vazquez has maintained their bullish stance on NEOG stock, giving a Buy rating on April 10.
Brandon Vazquez’s rating is based on a comprehensive analysis of Neogen’s strategic adjustments and market positioning. The company’s decision to focus its genomic services business primarily on bovine is expected to streamline operations and align with market demands, despite the anticipated decline in annual revenue from this segment.
Additionally, Vazquez has taken into account the company’s proactive approach to managing potential challenges, such as adjusting gross margin estimates to account for the evolving tariff landscape, particularly with China. These strategic moves indicate a robust long-term growth potential, justifying the Buy rating.
In another report released on April 10, Guggenheim also reiterated a Buy rating on the stock with a $13.00 price target.